NASDAQ:YDES • KYG983011076
The current stock price of YDES is 8.022 USD. In the past month the price decreased by -34.78%.
ChartMill assigns a fundamental rating of 3 / 10 to YDES. While YDES seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months YDES reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS decreased by -10100% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.17% | ||
| ROE | -27.74% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
YD Bio Ltd. engages in the development of detection and therapeutic technologies. The company is headquartered in Taipei City, Taipei and currently employs 5 full-time employees. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.
YD BIO LTD
12F, No. 3, Xingnan Street, Nangang District
Taipei City TAIPEI TW
Employees: 5
Phone: 88623820330
YD Bio Ltd. engages in the development of detection and therapeutic technologies. The company is headquartered in Taipei City, Taipei and currently employs 5 full-time employees. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.
The current stock price of YDES is 8.022 USD. The price decreased by -8.84% in the last trading session.
YDES does not pay a dividend.
YDES has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
YD BIO LTD (YDES) currently has 5 employees.
YD BIO LTD (YDES) has a market capitalization of 565.71M USD. This makes YDES a Small Cap stock.